Colonial Trust Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Colonial Trust Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$510	–	933
2023 Q2	$510	Hold	5	–	–	﹤0.01%	838
2023 Q1	$455	Hold	5	–	–	﹤0.01%	838
2022 Q4	$190	Buy	+5	New	+$172	﹤0.01%	871

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Colonial Trust Advisors's RETA Position: Q3 2023 in Review

Colonial Trust Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5 shares — an estimated $510 sold.

Colonial Trust Advisors first reported a position in RETA in Q4 2022 and held it in 3 quarters. The position peaked at $510 in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Colonial Trust Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Colonial Trust Advisors sold 5 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $510.
Colonial Trust Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 3 quarters.
Colonial Trust Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $510 in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Colonial Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.